Study IDs Targetable Signaling Alterations in Risky ALL Subtype | GenomeWeb

NEW YORK (GenomeWeb) – In a genomic study of the childhood cancer acute lymphoblastic leukemia, a St. Jude Children's Research Hospital-led team participating in the Pediatric Cancer Genome Project has tracked down recurrent alterations that may be susceptible to tyrosine kinase inhibitors.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In PNAS this week: carbapenem resistance in Enterobacteriaceae, selection against educational attainment-linked variants, and more.

Technology Review points out that a new US presidential science advisor hasn't been selected.

Researchers find that blood tests might be able to help determine severity of a concussion, Wired reports.

President-elect Donald Trump considers other candidates for director of the National Institutes of Health, Nature News reports.